PATENT CLAIM ANALYSIS

Application Number: 15891238
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "001100"]

Abstract:
A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.

Claim (Index 17):
The method according to  claim 16 , wherein the cell is an antigen presenting cell.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.21429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14424981', '13535297', '14667560', '14079144', '13535303']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7844168606907946
- 35 USC 102 Novelty (BERT): 0.5996939782328512
- Combined Prediction Score: 0.7659445724450004
- Mean Citation Score: 428.86909800000006
- Max Citation Score: 593.4217
- Similarity Product: 410.6926851101756

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test